Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome

Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K and Devroey P (2000) Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod15, 526–531.

Al-Inany H and Aboulghar M (2002) GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod17, 874–885.

Asch RH, Li HP, Balamceda JP, Weckstein LN and Stone SC (1991) Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod6, 1395–1399.

Crooke AC (1970) Induction of ovulation with gonadotrophins. Br Med Bull26, 17–21.

Delvigne A and Rozenberg S (2002) Epidemiology and prevention of ovarian hypersstimulation syndrome (OHSS): a review. Hum Reprod Update8, 559–577.

Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, Englert Y, Delbeke L, Darcis L, Gordts S et al. (1993) The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I: Clinical and biological features. Hum Reprod8, 1353–1360.

Enskog A, Henriksson M, Unander M, Nilsson L and Brannstrom M (1999) Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril71, 808–814.

European-Middle East Orgalutran Study Group (2001) Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod16, 644–651.

European Orgalutran Study Group (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod15, 1490–1498.

Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W et al. (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril75, 38–45.

Forman RG, Frydman R, Egan D, Ross C and Barlow DH (1990) Severe ovarian hyperstimulation syndrome using agonist of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril53, 502–509.

Haning RV Jr, Austin CW, Carlson IH, Kuzma DL, Shapiro SS and Zweibel WJ (1983) Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril40, 31–36.

Kulikowski M, Wolczynski S, Kuczynski W, Grochowski D and Szamatowicz M (1995) Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. Gynecol Endocrinol9, 97–102.

Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmüller-Winzen H, Schüler A, Engel W and Diedrich K (2000) Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonists Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet264, 29–32.

Ludwig M, Katalinic A and Diedrich K (2001) Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet265, 175–182.

MacDougall MJ, Tan SL and Jacobs HS (1992) In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod7, 597–600.

Machin D, Campbell M, Fayers P and Pinol A (1997) Sample Size Tables for Clinical Studies. 2nd. Blackwell Science, Oxford, UK.

Marthur RS, Akande AV, Keay SD, Hunt LP and Jenkins JM (2000) Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril73, 901–907.

Mordel N and Schenker JG (1993) Gonadotrophin-releasing hormone agonists and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod8, 2009–2014.

Navot D, Relou A, Birkenfels A, Rabinowitz R, Brzezinski A and Margalioth EJ (1988) Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol159, 210–215.

Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P and Frydman R (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril73, 314–320.

Penzias AS (2002) Luteal phase support. Fertil Steril77, 318–323.

Raga F, Casañ EM, Dubon MD, Marti R, Bonilla-musoles F and Polan ML (2002) Modulation of vascular endothelial growth factor by GnRH analogues: potential use in clinical management of ovarian hyperstimulation syndrome. Abstract presented at the 18th Meeting of the European Society of Human Reproduction and Embryology. Hum Reprod17 (Suppl 1), 14 (abstract O-037).

Rizk B and Smitz J (1992) Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod7, 320–327.

Segal S and Casper RF (1992) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil Steril57, 1254–1258.

Shalev E, Geslevich Y, Matilsky M and Ben-Ami M (1995) Induction of pre-ovulatory gonadotrophin surge with gonadotrophin-releasing hormone agonist compared to pre-ovulatory injection of human chorionic gonadotrophins for ovulation induction in intrauterine insemination treatment cycles. Hum Reprod10, 2244–2247.